3-{1-methyl-7-oxo-3-propyl-1H,4H,7H-pyrazolo[4,3-d]pyrimidin-5-yl}-N-[2-(1-methylpyrrolidin-2-yl)ethyl]-4-propoxybenzene-1-sulfonamide

• ChemBase编号: 4423
• 分子式: C25H36N6O4S
• 平均质量: 516.65614
• 单一同位素质量: 516.25187466
• SMILES: S(=O)(=O)(NCCC1N(CCC1)C)c1cc(c2[nH]c3c(nn(c3c(=O)n2)C)CCC)c(OCCC)cc1
• Canonical SMILES: CCCOc1ccc(cc1c1nc(=O)c2c([nH]1)c(CCC)nn2C)S(=O)(=O)NCCC1CCCN1C
• InChI: InChI=1S/C25H36N6O4S/c1-5-8-20-22-23(31(4)29-20)25(32)28-24(27-22)19-16-18(10-11-21(19)35-15-6-2)36(33,34)26-13-12-17-9-7-14-30(17)3/h10-11,16-17,26H,5-9,12-15H2,1-4H3,(H,27,28,32)
• InChIKey: IYFNEFQTYQPVOC-UHFFFAOYSA-N

名称和登记号

名称

• IUPAC标准名: 3-{1-methyl-7-oxo-3-propyl-1H,4H,7H-pyrazolo[4,3-d]pyrimidin-5-yl}-N-[2-(1-methylpyrrolidin-2-yl)ethyl]-4-propoxybenzene-1-sulfonamide
• IUPAC传统名: @udenafil; udenafil
• 商标名: Zydena
• 别名: Udenafil

登记号

• CAS号: 268203-93-6
• PubChem SID: 99443240; 160967855
• PubChem CID: 6918523
• Chemspider ID: 5293720
• DrugBank ID: DB06267
• KEGG ID: D10027
• 美国药典/FDA物质标识码: L5IB4XLY36
• 维基百科标题: Udenafil

理论计算性质

JChem

• Acid pKa: 7.2116613
• 质子受体: 8
• 质子供体: 2
• LogD (pH = 5.5): 0.11699866
• LogD (pH = 7.4): 1.5393687
• Log P: 1.6629407
• 摩尔折射率: 153.1134 cm^3
• 极化性: 53.998516 Å^3
• 极化表面积: 117.92 Å^2
• 可自由旋转的化学键: 10
• 里宾斯基五规则: false

ALOGPS 2.1

• Log P: 3.2
• LOG S: -3.81
• 溶解度: 7.98e-02 g/l

分子性质

药理学性质

• 半衰期: 7.3–12.1 hours

详细说明

DrugBank - DB06267

• Drug Groups: approved; investigational
• Description: Udenafil is a new phosphodiesterase type 5 (PDE5) inhibitor used to treat erectile dysfunction (ED). It has been approved in South Korea and will be marketed under the brand name Zydena. It is not yet approved for use in the U.S., E.U., or Canada.
• Indication: Investigated for use/treatment in erectile dysfunction and hypertension.
• Pharmacology: Udenafil is a potent selective phosphodiesterase type 5 (PDE5) inhibitor.
• Affected Organisms: Humans and other mammals
• Biotransformation: Hepatic. Metabolized by CYP3A4 and CYP3A5.
• References: Ji HY, Shim HJ, Yoo M, Park ES, Lee HS: Transport of a new erectogenic udenafil in Caco-2 cells. Arch Pharm Res. 2007 Sep;30(9):1168-73. [Pubmed] ; Ku HY, Ahn HJ, Seo KA, Kim H, Oh M, Bae SK, Shin JG, Shon JH, Liu KH: The contributions of cytochromes P450 3A4 and 3A5 to the metabolism of the phosphodiesterase type 5 inhibitors sildenafil, udenafil, and vardenafil. Drug Metab Dispos. 2008 Jun;36(6):986-90. Epub 2008 Feb 28. [Pubmed]
• External Links: Wikipedia

参考文献

• Ji HY, Shim HJ, Yoo M, Park ES, Lee HS: Transport of a new erectogenic udenafil in Caco-2 cells. Arch Pharm Res. 2007 Sep;30(9):1168-73. Pubmed
• Ku HY, Ahn HJ, Seo KA, Kim H, Oh M, Bae SK, Shin JG, Shon JH, Liu KH: The contributions of cytochromes P450 3A4 and 3A5 to the metabolism of the phosphodiesterase type 5 inhibitors sildenafil, udenafil, and vardenafil. Drug Metab Dispos. 2008 Jun;36(6):986-90. Epub 2008 Feb 28. Pubmed